WILMINGTON, Del., Nov. 3 /PRNewswire-FirstCall/ -- Millenia Hope, Inc. (OTC Bulletin Board: MLHP), an international bio-pharma company, announced today it has added Dr. E. Vandeweghe to its Advisory Board (Corporate Advisory Board which is instrumental in assisting with fund development, advocacy, public awareness, and strategic planning). The Corporate Advisory Board (CAB) will consist of recognized industry leaders from the corporate and government communities. Each CAB representative possesses strong personal and professional interest in the growth of Millenia Hope. The representatives have culminated through their skills and successes the respect and knowledge which they command in their respective industry. They also share a common concern for the financial welfare and perpetual growth of Millenia Hope, Inc. and its mission to save lives. Mr. Leonard Stella, Chairman and CEO of Millenia Hope, Inc., stated, "It is with great pleasure and enthusiasm that we welcome Dr. Vandeweghe to Millenia Hope, Inc. This marks another important milestone in the pursuit of the Company's objectives. With the corporate guidance and vigilance of its experienced Advisory Board, the Company hopes to attract other strategic advisors with the charter to assist and facilitate the Company's global expansion, development and distribution of new products." These initiatives are all necessary steps to the recognition of Millenia Hope as a leader in the fight against malaria and other life-threatening diseases. ABOUT DR. VANDEWEGHE Presently Dr. Vandeweghe is a consultant and principal with Focus Partners West LLC, CB Capital, and The United States Golf and Fitness Association (USGFA). He has also been Chairman and advisor to many charities and causes as well as the President's Council on Physical Fitness and Sports. While participating in President Ford's Olympic Sports Commission, Dr. Vandeweghe was instrumental in developing the 1976 Amateur Athletic Act, Title IX and securing funding for athletes and sports from the corporate community. Dr. Vandeweghe has extensive banking background experience commencing with Oceanside National Bank and Valley National Bank (Long Island, NY) and later joined Bank of New York (BONY). He has served as a consultant and financial advisor to many corporations, prominent individuals and athletes. Dr. Vandeweghe, a former NBA all-star himself, married Colleen Kay Hutchins (former Miss America) over 50 years ago and together they have 4 children, Ernest III (Kiki), General Manager of the Denver Nuggets, Tauna Kay O'Shea (former US Olympian - swimming, volleyball), Heatherly Shannon, MD (Attending Physician UCLA) and Burk (professional trainer, world-class volleyball). Dr. Vandeweghe has made many appearances in national events, is a member of several Halls of Fame and is an entertaining speaker. He is perhaps one of the most personable and recognized sports figures in history. Dr. Vandeweghe may be contacted via FOCUS Partners West @ (858) 405-5498 or (858) 759-0151. ABOUT DR. HAGAI GINSBURG To clarify our previous statement: Dr. Ginsburg is a globally recognized expert on malaria, having published many dozens articles and book chapters on the subject. He has been consulted by the WHO/TDR malaria (the World Health Organization), the Welcome Trust and numerous other organizations and individual malaria researchers and experts. He is an Emeritus Professor at the Hebrew University of Jerusalem. ABOUT MILLENIA HOPE The Company conducts research and development to solve under-served or unmet medical needs globally. The Company's current focus is on anti-malarial agents for whom it has secured approval for distribution in 18 African countries and the Dominican Republic. Other applications are in various stages of negotiation and approval. Millenia's Malaria treatment MMH(TM) Malarex/MMH(TM)18 has achieved significant results via its clinical trials in Africa. Over 700 patients consisting of patients of all ages, having taken part in the studies, were "cured" of the disease. This is especially remarkable considering CDC data indicates as much as a 75% treatment failure rate of the most commonly used medications, while enduring a 50% global increase in malaria cases since 1998. Millenia Hope, Inc. is an international bio-pharma company developing treatments and products that will increase the quality of life, provide tools in the fight against diseases and promote healthier lives. The Company is committed to research and development to deliver solutions for global medical needs and to bring hope through healthcare and innovative approaches to curing and mitigating disease worldwide. For further information including a fact-sheet on the Company please contact FOCUS Partners West LLC. Safe Harbor Statement This press release may contain forward-looking statements that involve risks and uncertainties, which may include statements about business strategy and development plans, plans for entering into new business, anticipated sources of funds, including the proceeds from future operations and plans, objectives, expectations and intentions contained in this Press Release that are not historical facts. When used in this Press Release, the word "expects," "intends," "projects," "plans," "believes," "seeks," "estimates" and similar expressions are generally intended to identify forward-looking statements. Because these forward-looking statements involve risk and uncertainties, actual results could differ materially from those discussed in this Press Release. These risks are outlined in our SEC filings.

This release was issued through eReleases(TM).

For more information, visit http://www.ereleases.com

SOURCE Millenia Hope Inc.